Company Filing History:

10 out of 44

Tanox Biosystems, Inc.

patents

1 out of 31

Tanox, Inc.

patents

Years Active: 1992-1999

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5981278 - Chimeric monoclonal antibodies which neutralize HIV-1 infection and (1999-11-09),

2. 5834599 - Immunoconjugates which neutralize HIV-1 infection (1998-11-10),

3. 5449760 - Monoclonal antibodies that bind to soluble IGE but do not bind IGE on (1995-09-12),

4. 5428133 - Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE (1995-06-27),

5. 5422258 - Methods for producing high affinity anti-human IgE-monoclonal antibodies (1995-06-06),

6. 5420251 - Anti-idiotype antibodies specific for the parotope of antibodies which (1995-05-30),

7. 5260416 - Antigenic epitopes present on membrane-bound but not secreted IgE (1993-11-09),

8. 5149782 - Molecular conjugates containing cell membrane-blending agents (1992-09-22),

9. 5091313 - Antigenic epitopes of IgE present on B cell but not basophil surface (1992-02-25),

10. 5089603 - Antigenic epitopes present on membrane-bound but not secreted IgA (1992-02-18),

11. 5079344 - Antigenic epitopes present on membrane-bound but not secreted IgA (1992-01-07),

Title: Innovations of Tse-wen Chang in HIV-1 Research

Introduction

Tse-wen Chang is a notable inventor based in Houston, TX (US), recognized for his significant contributions to the field of biomedical research, particularly in the development of therapies targeting HIV-1. With a total of 11 patents to his name, Chang's work has the potential to impact the treatment and prevention of AIDS and related conditions.

Latest Patents

Chang's latest patents include groundbreaking innovations such as chimeric monoclonal antibodies that neutralize HIV-1 infection. These antibodies specifically bind to the gp120 protein on the envelope of HIV-1, effectively neutralizing the virus. They inhibit the rate of infection of T cells and prevent syncytium formation. Importantly, these antibodies are group-specific, allowing them to neutralize various strains and isolates of HIV-1. Their applications extend to the treatment and prevention of AIDS and AIDS-related complex (ARC). Another significant patent involves immunoconjugates that also neutralize HIV-1 infection, utilizing the same mechanism of action to target and inhibit HIV-1 infected T cells.

Career Highlights

Throughout his career, Tse-wen Chang has worked with prominent companies in the biotechnology sector, including Tanox Biosystems, Inc. and Tanox, Inc. His innovative research has positioned him as a key figure in the fight against HIV-1, contributing to advancements that could lead to more effective treatments.

Collaborations

Chang has collaborated with notable colleagues in his field, including Nancy T. Chang and Bill Nai-Chau Sun. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in HIV research.

Conclusion

Tse-wen Chang's contributions to HIV-1 research through his patents and collaborations highlight his commitment to advancing medical science. His work not only addresses critical health challenges but also paves the way for future innovations in the treatment and prevention of viral infections.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.